07/15/2026
WPS Oncology Related LCD Updates
July Updates
July 2026 Local Coverage Determination (LCD) and Billing and Coding Article Updates
We updated the following Local Coverage Determinations (LCDs) and Billing and Coding Articles for July 2026. The full article on our website details additional information on these updates.
Please note: Our LCDs and Billing and Coding/Coverage articles will reflect these changes on June 25, 2026.
New Policies/Articles – We created the following new policies/articles for July 2026 – Effective as Indicated
- Billing and Coding: MolDx: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis – Effective August 10, 2026
- MolDx: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis – Effective August 10, 2026
- Response to Comments MolDx: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis – Effective June 25, 2026
Retired Policies/Articles – We retired no policies/articles for July 2026.
Revised Policies/Articles – We revised the following policies/articles for July 2026 – Effective as Indicated
- Billing and Coding: Colonoscopy and Sigmoidoscopy-Diagnostic – Effective June 25, 2026
- Billing and Coding: Cosmetic and Reconstructive Surgery – Effective June 25, 2026
- Billing and Coding: Endometrial Hyperplasia Treatment with Intrauterine Device (Hormone-Eluting) – Effective June 25, 2026
- Billing and Coding: Intraarticular Knee Injections of Hyaluronan – Effective June 25, 2026
- Billing and Coding: Micro-Invasive Glaucoma Surgery – Effective June 1, 2026
- Billing and Coding: MolDx: Minimal Residual Disease Testing for Solid Tumor Cancers – Effective June 25, 2026
- Billing and Coding: MolDx: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer – Effective June 25, 2026
- Billing and Coding: MolDx: Next-Generation Sequencing for Solid Tumors – Effective June 4, 2026